Obesity
Conditions
Keywords
Obesity, Endoscopic sleeve gastroplasty, Weight loss
Brief summary
Weight loss is of paramount importance to ameliorate obesity-related complications. Endoscopic sleeve gastroplasty is a new therapeutic option to obtain significant weight reduction in obese patients. Nevertheless, a only a part of patients experience sufficient weight loss to improve comorbidities. A better understanding of mechanisms driving body weight trajectory after endoscopic sleeve gastroplasty may help patient selection and improve efficacy. The main aim of this study is to identify factors associated with weight reduction after endoscopic sleeve gastroplasty in patients with overweight or morbid obesity without indication to bariatric surgery. For this purpose, the investigators conduct a retro-prospective cohort study including patients with overweight or moderate obesity undergoing endoscopic sleeve gastroplasty between March 2017 and March 2023
Detailed description
The prevalence of obesity is increasing worldwide, and it is estimated that one quarter of the world's population will be overweight or obese by 2045. Obesity can lead to complications, including cardiovascular damage (myocardial ischemia and stroke), liver damage (non-alcoholic steatohepatitis and liver cancer), diabetes and extra-hepatic cancers. In this context, achievement of a significant long-term weight loss is of paramount importance to ameliorate patient outcome. Bariatric surgery is the most effective treatment for severe obesity and results in a significant long-term weight loss. However, bariatric surgery is restricted to patients with a BMI \>40 kg/m2 or \>35 kg/m2 with commodities (hypertension, diabetes, sleep apnoea, NASH). Therefore, the majority of obese patients do not benefit from this procedure. Recent advances in flexible endoluminal endoscopy now provide the tools for transoral endoscopic gastric volume reduction (ESG, endoscopic sleeve gastroplasty). The gastric body is reduced by an endoscopic procedure involving suture plications. This minimally invasive method may be a good therapeutic option to obtain a significant weight reduction in patients with moderate obesity or those with severe obesity and no indication for bariatric surgery (BMI between 35 and 40 kg/m2 without commodities). In this context this study aims to identify predictive factors of weight loss following ESG and explore changes of metabolic parameters, metabolomic profiles and gut microbiota profiles. This is a retro-prospective cohort study including patients with moderate obesity undergoing ECG between March 2017 and September 2023. Clinical parameters (weight, high, BMI, weight fluctuations), serum metabolic parameters (standard lipid profile, lipoprotein levels, fasting plasma glucose, insulin levels, C-peptide levels, hemoglobin A1c) and liver function test parameters (standard biology, transient elastometry, Fibrotest®, Actitest®, abdominal ultrasound) are systematically collected for all patients before ESG and then at three- and twelve-month post-ESG. Samples of serum, plasma, stools and saliva are also systematically collected for research purpose before ESG and then at three- and twelve-month post-ESG. Each sample is stored at -80°C for subsequent analysis. Metabolomic/lipidomic analysis will be used to quantify metabolite and lipid species in serum/plasma samples. Metagenomic analysis will be used to characterise faecal and salivary microbiota profiles.
Interventions
OTHEROBPLUS Clinical Database : data analysis
The data processed relates to patients cared for in the Hepato-gastroenterology and nutrition department of the Antoine Béclère Hospital at the Assistance Publique - Hôpitaux de Paris (AP-HP. All of the clinical and paraclinical data are collected during the visits and entered into the OBPLUS database (database registered in the AP-HP register). These data will be analyzed in order to identify the predictive factors of the effectiveness of the fundo-plication.
OTHERBiological collection "Liver, bile ducts and pancreas": sample analysis
The samples (plasma, serum, saliva, stool) collected during the samples taken as part of the patient's care were the subject of a biological collection "Liver, bile ducts and pancreas". These samples will be analyzed in order to identify the predictive factors of the effectiveness of the fundo-plication.
Sponsors
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé Et de la Recherche Médicale, France
INSERM U996
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥18 years * Patients giving their consent for the study * Body mass index between 28 and 35 kg/m2 with co-morbid condition (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, non-alcoholic fatty liver disease or invalidating joint pain) * No weigh loss following life-style changes
Exclusion criteria
* Antibiotic treatment during the three previous months * Patients at risk of gastric cancer requiring regular endoscopic surveillance * Gastric localization of Crohn disease * Portal hypertension * Severe hepatic or renal failure * Ongoing peptic ulcer * Severe associated disease * History of previous bariatric surgery
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum metabolite profile using widely targeted metabolomics according to weigh loss amount (less than 10% of total weight versus more than 10% of total weight loss at 12 months post-surgery) | Before endoscopic sleeve gastroplasty | A volume of 50 µl of serum/plasma will be used for analysis of serum metabolites using widely targeted metabolomics mass spectrometry. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical parameters at baseline and then at 3 and 12 month post-intervention. | Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12 | Weight expressed in kg, percentage of total weight loss and percentage of excessed weight loss will be analysed as they are systematically available in usual clinical practice. |
| Basic serum lipid profile at baseline and then at 3 and 12 month post-intervention. | Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12 | Basic serum lipid profile will be analysed by spectrometry as they are systematically available in usual clinical practice. |
| Glycated hemoglobin at baseline and then at 3 and 12 month post-intervention. | Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12 | Glycated hemoglobin expressed in % will be analysed as they are systematically available in usual clinical practice. |
| Insulin at baseline and then at 3 and 12 month post-intervention. | Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12 | Insulin expressed in mUI/l will be analysed as it is systematically available in usual clinical practice. |
| C peptide at baseline and then at 3 and 12 month post-intervention. | Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12 | C peptide expressed in µg/l will be analysed as it is systematically available in usual clinical practice. |
| Ferritin at baseline and then at 3 and 12 month post-intervention. | Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12 | Ferritin expressed in µg/l will be analysed as it is systematically available in usual clinical practice. |
| Liver function test parameter Alanine transaminase (ALT) at baseline and then at 3 and 12 month post-intervention. | Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12 | ALT levels expressed in IU/l will be analysed as they are systematically available in usual clinical practice. |
| Liver function test parameter aspartate transaminase (AST) at baseline and then at 3 and 12 month post-intervention. | Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12 | AST levels expressed in IU/l will be analysed as they are systematically available in usual clinical practice. |
| Liver function test parameter Gamma-glutamyltransferase (GGT) at baseline and then at 3 and 12 month post-intervention. | Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12 | GGT levels expressed in IU/l will be analysed as they are systematically available in usual clinical practice. |
| Liver function test parameter Alkaline phosphatase (ALP) at baseline and then at 3 and 12 month post-intervention. | Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12 | ALP levels expressed in IU/l will be analysed as they are systematically available in usual clinical practice. |
| Liver fibrosis assessed by transient elastometry at baseline and then at 3 and 12 month post-intervention | Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12 | Transient elastometry expressed in kPa will be analysed as they are systematically available in usual clinical practice. |
| Liver steatosis assessed by controlled attenuation parameter (CAP) at baseline and then at 3 and 12 month post-intervention. | Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12 | Controlled attenuation parameter expressed in dB/m will be analysed as they are systematically available in usual clinical practice. |
| Serum metabolites using widely targeted metabolomics at baseline and then at 3 and 12 month post-intervention. | Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12 | A volume of 50 µl of serum/plasma will be used for analysis of serum metabolites using widely targeted metabolomics by mass spectrometry. |
| Complications of endoscopic sleeve gastroplasty | During the first week post-endoscopic sleeve gastroplasty and at Month 3 and Month 12 | Data on the potential complications (occurrence of perforation, bleeding, peritonitis and other infections, thrombo-embolic events and death) of endoscopic sleeve gastroplasty will be collected. |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORCosmin VOICAN, MD, PhD
APHP, Antoine-Béclère Hospital
Outcome results
None listed